New CCDS guidelines aim to standardize canine dementia diagnosis

A new international consensus statement is giving veterinarians something the CCDS field has lacked for years: a common definition of canine cognitive dysfunction syndrome, plus a practical way to diagnose and monitor it in everyday practice. Published in JAVMA on December 24, 2025, the guidance was developed by the CCDS Working Group led by North Carolina State University’s Natasha Olby and is being described by NC State, AAHA, and the AKC Canine Health Foundation as the first published guidelines of their kind for canine dementia. (news.ncsu.edu)

The push for consensus came from a familiar clinical problem: senior dogs are living longer, but veterinarians have had limited standardized tools to separate normal aging from true cognitive disease. A 2025 survey of U.S. practitioners found there were no accepted guidelines for diagnosis and management at the time, and practice patterns varied widely. That matters because CCDS can look like many other conditions, from sensory decline and pain to intracranial disease, making overdiagnosis and underdiagnosis equally plausible in general practice. (pubmed.ncbi.nlm.nih.gov)

The new framework starts by defining CCDS as a chronic, progressive, age-associated neurodegenerative syndrome characterized by cognitive and behavioral changes that affect daily life. The working group anchors case recognition in the DISHAA domains: disorientation, social interaction changes, sleep disruption, house soiling together with learning and memory deficits, activity changes, and anxiety. It also proposes three severity stages, from mild to severe, to help clinicians and pet parents describe impact over time in more consistent terms. In practice, that history is still built largely from owner observations, often using standardized tools such as the Canine Dementia Scale, the Canine Cognitive Dysfunction Rating Scale, and the DISHA questionnaire. (news.ncsu.edu)

The most practice-relevant piece may be the two-tier diagnostic model. Level 1 is intended to be clinically usable in primary care and depends on a consistent history of progressive DISHAA signs, physical, orthopedic, and neurologic examination, laboratory work, and either a normal neurologic exam or evidence of symmetrical diffuse forebrain dysfunction. It also requires that signs persist after management of relevant comorbidities. Level 2 adds advanced support for the diagnosis through MRI evidence of cortical atrophy and CSF cell counts within normal limits. Definitive confirmation, the group notes, still remains postmortem. (news.ncsu.edu)

Olby and other commentators have been explicit that the document is meant as a starting point, not the final word. In NC State’s release, Olby said the field first needed “an agreed upon definition” before better treatments could be developed. In AAHA’s coverage, she also emphasized the practical constraints many clinics face: a full workup with MRI and CSF is not realistic for every patient because of cost, anesthesia risk, and workflow limitations. That tension helps explain why the group built a framework that can support both real-world primary care and more rigorous specialty-level evaluation. The same practical mindset is showing up in how some clinicians talk about implementation: in a recent veterinary podcast discussion of the guidelines, behaviorist Lisa Radosta described tracking mentation in dogs starting around age 7, mirroring the paper’s emphasis on earlier, routine surveillance rather than waiting for advanced decline. (news.ncsu.edu)

Industry reaction has been broadly supportive. The AKC Canine Health Foundation, which helped support the work, said the guidelines create a shared scientific language that should improve care and accelerate discovery, and it has since launched an aging dog dementia resource hub to extend those materials to veterinarians and pet parents. That kind of infrastructure matters because consensus definitions do more than tidy up terminology; they make research cohorts more comparable, outcome measures more interpretable, and client communication more concrete. It also strengthens CCDS as a translational model for human Alzheimer’s disease, where dogs and people share important clinical and molecular features, including amyloid-β accumulation and tau-related pathology, even if the canine tau picture appears to be dominated more by pre-tangle synaptic hyperphosphorylation than by abundant classic neurofibrillary tangles. (akcchf.org)

Why it matters: For veterinary professionals, the immediate value is less about a new test and more about a cleaner clinical pathway. The guidelines formalize the idea that CCDS is a diagnosis reached only after defining the syndrome carefully and excluding competing explanations for behavioral change. That should help teams structure senior-dog visits, decide when to escalate diagnostics, and talk with pet parents about uncertainty, prognosis, and monitoring. It may also improve case selection for emerging therapies and biomarker studies, an important point as reviews published in 2026 point to active work on blood- and CSF-based markers. Among those, neurofilament light chain currently looks like the strongest candidate for staging and longitudinal monitoring because CSF and plasma levels rise with age, correlate with cognitive impairment, and appear to reflect central axonal injury. Amyloid-β measures, including Aβ42 and Aβ42/Aβ40 ratios, may also prove useful but seem to change in more stage-dependent, non-linear ways; GFAP remains exploratory, and exosomal microRNAs are being studied as another possible early-detection signal. (news.ncsu.edu)

Another reason the guidelines matter is that they create a framework into which future objective measures can fit. NC State researchers have already reported that shorter height-adjusted thoracic limb stride length is associated with worse owner-reported cognitive impairment in aging dogs, even after accounting for age and pain scores. The effect is modest and not diagnostic on its own, but it suggests gait-based functional measures could become useful adjuncts for monitoring progression over time, especially in longitudinal senior-care programs. At the same time, broader biologic models are attracting attention. Reviews of the microbiota-gut-brain axis in veterinary medicine suggest dysbiosis may contribute to neuroinflammation, oxidative stress, immune dysregulation, and blood-brain barrier disruption in dogs with behavioral and neurologic disease, including CCDS, raising the possibility that gut-targeted interventions could eventually complement brain-focused care.

What to watch: The next milestones are likely to be adoption of routine screening protocols, validation of practical cognitive testing batteries, and development of objective biomarkers that can move CCDS closer to the diagnostic model used in human neurodegenerative disease. For now, the working group recommends beginning routine monitoring for cognitive change around age 7, using follow-up CCDS scales when concerns are raised, and shifting to every-6-month screening for all dogs beginning at age 10. If those workflows become routine, the field will be better positioned to test multimodal monitoring strategies that combine owner questionnaires, neurologic assessment, imaging when appropriate, and newer tools such as blood biomarkers or functional gait measures. (news.ncsu.edu)